Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Type 2 diabetes mellitus (T2DM) is the predominant form, accounting for over 90% of all diabetes cases globally
The quite unexpected positive cardiorenal outcomes that have emerged from the cardiovascular outcomes trials (CVOTs) with both glucagon like peptide-1 receptors agonists (GLP-1RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have produced a shift of diabetes management from the meticulous glycemic control alone to the simultaneous improvement of CV outcomes
In addition to their role in insulin secretion, GLP-1R agonists can also contribute to weight management, decrease the potential for cardiovascular diseases and protect beta cells
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
US$ 25.93
US$ 27.04
US$ 21.38
US$ 21.93
US$ 27.48
US$ 25.92
US$ 24.19
.png)
US$ 25.86
US$ 29.67
